Publicação: IL-12 and neutralization of endogenous IL-10 revert the in vitro antigen-specific cellular immunosuppression of paracoccidioidomycosis patients
dc.contributor.author | Romano, Carla C. | |
dc.contributor.author | Mendes-Giannini, Maria José Soares [UNESP] | |
dc.contributor.author | Duarte, Alberto J.S. | |
dc.contributor.author | Benard, Gil | |
dc.contributor.institution | Universidade de São Paulo (USP) | |
dc.contributor.institution | Universidade Estadual Paulista (Unesp) | |
dc.date.accessioned | 2014-05-27T11:20:29Z | |
dc.date.available | 2014-05-27T11:20:29Z | |
dc.date.issued | 2002-07-25 | |
dc.description.abstract | Treatment of patients with paracoccidioidomycosis is still a challenge. Patients present defective lymphoproliferation and IFN-γ responses to the main Paracoccidioides brasiliensis antigen (gp43), which correlates with disease severity. Here, we demonstrated that the patients show also a defective synthesis of interleukin (IL)-12. Therefore, we attempted to revert this immune disfunction by adding IL-12 and neutralizing anti-IL-10 antibody to gp-43-stimulated peripheral blood mononuclear cell cultures. Both treatments increased IFN-γ secretion to levels observed with healthy sensitized individuals, but affected proliferation only modestly. When combined, the treatments further increased IFN-γ synthesis and cell proliferation. The addition of suboptimal concentrations of IL-2 also further increased the IL-12-mediated secretion of IFN-γ. Interestingly, the immune modulation was mostly antigen-specific, since the responses to Candida albicans' antigen were not affected. These results suggest that appropriate immune intervention with cytokines and/or anti-cytokines may help in the treatment of PCM. © 2002 Elsevier Science Ltd. All rights reserved. | en |
dc.description.affiliation | Laboratório de Alergia E Imunologia Clínica E Experimental LIM 56 Faculdade de Medicina Universidade de São Paulo | |
dc.description.affiliation | Departamento de Análises Clínicas Da Faculdade de Ciências Farmacêuticas UNESP, Araraquara | |
dc.description.affiliation | Clínica de Doenças Infecciosas E Parasitárias Hospital Das Clínicas Da FMUSP, São Paulo | |
dc.description.affiliationUnesp | Departamento de Análises Clínicas Da Faculdade de Ciências Farmacêuticas UNESP, Araraquara | |
dc.format.extent | 149-157 | |
dc.identifier | http://dx.doi.org/10.1006/cyto.2002.0884 | |
dc.identifier.citation | Cytokine, v. 18, n. 3, p. 149-157, 2002. | |
dc.identifier.doi | 10.1006/cyto.2002.0884 | |
dc.identifier.issn | 1043-4666 | |
dc.identifier.orcid | 0000-0002-8059-0826 | |
dc.identifier.scopus | 2-s2.0-0035997261 | |
dc.identifier.uri | http://hdl.handle.net/11449/66938 | |
dc.identifier.wos | WOS:000177591000005 | |
dc.language.iso | eng | |
dc.relation.ispartof | Cytokine | |
dc.relation.ispartofjcr | 3.514 | |
dc.relation.ispartofsjr | 1,433 | |
dc.rights.accessRights | Acesso restrito | pt |
dc.source | Scopus | |
dc.subject | Interleukin-10 | |
dc.subject | Interleukin-12 | |
dc.subject | Paracoccidioides brasiliensis | |
dc.subject | Paracoccidioidomycosis | |
dc.subject | gamma interferon | |
dc.subject | glycoprotein | |
dc.subject | glycoprotein gp 43 | |
dc.subject | interleukin 10 | |
dc.subject | interleukin 12 | |
dc.subject | interleukin 2 | |
dc.subject | neutralizing antibody | |
dc.subject | unclassified drug | |
dc.subject | 43 kDa protein, Paracoccidioides | |
dc.subject | fungal protein | |
dc.subject | fungus antigen | |
dc.subject | oligosaccharide | |
dc.subject | adolescent | |
dc.subject | adult | |
dc.subject | aged | |
dc.subject | cell proliferation | |
dc.subject | cell stimulation | |
dc.subject | clinical article | |
dc.subject | controlled study | |
dc.subject | cytokine production | |
dc.subject | cytokine release | |
dc.subject | human | |
dc.subject | immune deficiency | |
dc.subject | immune response | |
dc.subject | immunomodulation | |
dc.subject | lymphocyte proliferation | |
dc.subject | mononuclear cell | |
dc.subject | priority journal | |
dc.subject | school child | |
dc.subject | South American blastomycosis | |
dc.subject | biosynthesis | |
dc.subject | child | |
dc.subject | drug antagonism | |
dc.subject | drug effect | |
dc.subject | immunological tolerance | |
dc.subject | immunology | |
dc.subject | in vitro study | |
dc.subject | lymphocyte activation | |
dc.subject | middle aged | |
dc.subject | Paracoccidioides | |
dc.subject | serodiagnosis | |
dc.subject | Adolescent | |
dc.subject | Adult | |
dc.subject | Aged | |
dc.subject | Antigens, Fungal | |
dc.subject | Child | |
dc.subject | Glycoproteins | |
dc.subject | Human | |
dc.subject | Immune Tolerance | |
dc.subject | In Vitro | |
dc.subject | Interferon Type II | |
dc.subject | Lymphocyte Activation | |
dc.subject | Middle Age | |
dc.subject | Neutralization Tests | |
dc.subject | Oligosaccharides | |
dc.subject | Support, Non-U.S. Gov't | |
dc.subject | Fungal Proteins | |
dc.subject | Humans | |
dc.subject | Middle Aged | |
dc.subject | Candida | |
dc.subject | Candida albicans | |
dc.title | IL-12 and neutralization of endogenous IL-10 revert the in vitro antigen-specific cellular immunosuppression of paracoccidioidomycosis patients | en |
dc.type | Artigo | pt |
dcterms.license | http://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy | |
dspace.entity.type | Publication | |
relation.isDepartmentOfPublication | a83d26d6-5383-42e4-bb3c-2678a6ddc144 | |
relation.isDepartmentOfPublication.latestForDiscovery | a83d26d6-5383-42e4-bb3c-2678a6ddc144 | |
relation.isOrgUnitOfPublication | 95697b0b-8977-4af6-88d5-c29c80b5ee92 | |
relation.isOrgUnitOfPublication.latestForDiscovery | 95697b0b-8977-4af6-88d5-c29c80b5ee92 | |
unesp.author.orcid | 0000-0002-8059-0826[2] | |
unesp.campus | Universidade Estadual Paulista (UNESP), Faculdade de Ciências Farmacêuticas, Araraquara | pt |
unesp.department | Análises Clínicas - FCF | pt |